Non-vitamin K oral anticoagulants (NOACs) have largely replaced vitamin-K antagonists as the gold-standard anticoagulation therapy for patients with heart failure and atrial fibrillation.
What are the indications and optimal choice of NOACs in heart failure patients with atrial fibrillation?
This review highlights NOACs as the current gold-standard for anticoagulation in patients with concurrent heart failure and atrial fibrillation.
The management of heart failure (HF) and atrial fibrillation (AF) in real-world practice remains a debating issue, while the number of HF patients with AF increase dramatically. While it is unclear if rhythm or rate control therapy is more beneficial and under which circumstances, anticoagulation therapy is the cornerstone of the AF-HF patients' approach. Vitamin-K antagonists were the gold-standard during the past, but currently their usage is limited in specific conditions. Non-vitamin K oral anticoagulants (NOACs) have gained ground during the last ten years and considered as gold-standard of a wide spectrum of HF phenotypes. The current manuscript aims to review the current literature regarding the indications and the optimal choice and usage of NOACs in HF patients with AF.
Tsigkas et al. (Fri,) conducted a review in Heart failure and atrial fibrillation. Non-vitamin K oral anticoagulants (NOACs) vs. Vitamin-K antagonists was evaluated. Non-vitamin K oral anticoagulants (NOACs) have largely replaced vitamin-K antagonists as the gold-standard anticoagulation therapy for patients with heart failure and atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: